How do I set a price alert for PFE?

To set a PFE price alert on Stock Alarm Pro, navigate to the PFE quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for PFE?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for PFE. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for Pfizer?

Stock Alarm Pro supports over 125 trigger types for PFE: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about PFE price changes?

PFE alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for PFE alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for PFE and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

PFE Company Intelligence - Business Model, Drivers & Risks

Pfizer Inc.(PFE)

NYSEClosing price · checked 9:49 PM ETAbout this dataData status

$28.89▲0.06 (0.21%)

Extended:$28.93+0.04 (+0.13%)

WatchlistChart Studio

PFE(PFE)

PFE

Pfizer is a global pharmaceutical company with a diversified portfolio spanning primary care, oncology, rare diseases, vaccines, and biosimilars. The company operates through two primary segments: Biopharma (branded drugs including Eliquis, Vyndaqel, Ibrance) and Established Medicines (mature products and generics). Post-COVID normalization has pressured revenue as Comirnaty and Paxlovid sales decline from pandemic peaks, while the company focuses on its oncology pipeline including Seagen acquisition assets and cost restructuring to restore margin expansion.

HealthcareLarge-Cap Pharmaceutical Manufacturersmoderate - High fixed R&D costs (typically $10-12B annually) and commercial infrastructure create leverage when blockbusters succeed, but patent expirations and generic competition rapidly erode margins on individual products. The company's cost restructuring program targeting $4B+ in savings by 2024 aims to improve operating leverage as COVID revenues normalize.

Business Overview

01Biopharma segment (~70-75% of revenue): Branded innovative drugs including Eliquis (anticoagulant), Vyndaqel (cardiomyopathy), Ibrance (breast cancer), Prevnar (vaccine franchise)

02Established Medicines segment (~15-20%): Mature branded products and generic drugs in international markets

03COVID products (~10-15% declining): Comirnaty vaccine and Paxlovid antiviral, normalizing from pandemic peaks

Pfizer generates revenue through patent-protected branded pharmaceuticals with pricing power in developed markets, leveraging global commercial infrastructure across 125+ countries. The company invests 15-20% of revenue in R&D to maintain pipeline velocity, with profitability driven by blockbuster drugs generating $1B+ annual sales. Gross margins of 70%+ reflect manufacturing scale and patent protection, while operating leverage comes from spreading fixed R&D and SG&A costs across a diversified portfolio. The 2023 Seagen acquisition ($43B) added antibody-drug conjugate (ADC) technology and oncology assets to offset upcoming patent cliffs on Eliquis (2026-2028) and Ibrance.

What Moves the Stock

Pipeline readouts and FDA approvals, particularly in oncology (Seagen ADCs, Lorbrena expansion) and rare disease franchises

Eliquis revenue trajectory and patent cliff timing (Bristol-Myers Squibb co-markets, faces generic entry 2026-2028)

COVID product revenue guidance and normalization pace for Comirnaty and Paxlovid

Cost restructuring execution and operating margin expansion toward 30%+ targets

M&A activity and capital deployment decisions given $10B+ annual free cash flow generation

Watch on Earnings

Operational revenue growth excluding COVID products (underlying business health)Adjusted operating margin and cost savings realization from restructuring programsOncology portfolio growth rate, particularly Seagen asset integration and ADC uptakePipeline advancement milestones and regulatory submission timelinesFree cash flow generation and capital allocation priorities (dividends, buybacks, bolt-on M&A)

Risk Factors

Drug pricing reform and government negotiation mandates (IRA Medicare negotiation starting 2026) compressing pricing power on high-revenue products

Patent cliff exposure with Eliquis, Ibrance, and other blockbusters facing generic competition 2026-2030, requiring $20B+ in revenue replacement from pipeline

Regulatory approval risk and clinical trial failures, with oncology trials carrying 10-15% phase 3 success rates industry-wide

Intense competition in oncology from Merck (Keytruda), Bristol-Myers Squibb, and emerging biotech with novel mechanisms

Biosimilar erosion of established biologics portfolio, particularly in international markets with faster biosimilar adoption

Loss of commercial partnerships or co-promotion agreements (e.g., Bristol-Myers Squibb on Eliquis) affecting revenue retention

Elevated debt levels ($60B+ gross debt) from Seagen acquisition requiring deleveraging, limiting near-term M&A flexibility

Pension and post-retirement benefit obligations creating non-cash charges and funding requirements in rising rate environments

Currency exposure with 40-45% international sales creating translation headwinds when USD appreciates

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than GDP growth. However, elective procedures and diagnostic rates can fluctuate with economic conditions, affecting new patient starts. International sales (40-45% of revenue) face currency headwinds when USD strengthens, and emerging market demand shows modest correlation to local economic growth.

Interest Rates

Rising rates modestly pressure valuation multiples as pharma stocks compete with fixed income for yield-seeking investors, given Pfizer's 6%+ dividend yield. Higher rates increase financing costs for M&A activity and debt servicing on the $60B+ debt load from Seagen acquisition. However, the core business model is rate-insensitive, with minimal working capital financing needs and pricing power insulating margins from rate-driven cost inflation.

Credit

minimal - Pharmaceutical sales are primarily reimbursed by government programs (Medicare, Medicaid) and commercial insurers with strong credit profiles. Accounts receivable risk is low, and the business does not depend on consumer credit availability. However, government budget pressures and drug pricing reform debates create reimbursement risk independent of credit cycles.

Live Conditions

Russell 2000 FuturesS&P 500 FuturesDow Jones Futures

Profile

dividend - Pfizer attracts income-focused investors with its 6%+ dividend yield and history of consistent payouts, along with value investors seeking exposure to a diversified pharma portfolio trading at 10-12x forward earnings. The stock appeals to defensive healthcare allocators during economic uncertainty, though growth investors have rotated out post-COVID revenue normalization.

moderate - Beta typically 0.6-0.8, with lower volatility than broader market due to non-cyclical pharmaceutical demand. However, binary clinical trial events and patent cliff concerns create episodic volatility spikes. Post-pandemic normalization has increased volatility as investors reassess normalized earnings power.

Key Metrics to Watch

Operational revenue growth rate excluding COVID products (Comirnaty, Paxlovid)

Eliquis quarterly sales and market share trends ahead of patent expiration

Oncology portfolio growth rate, particularly Seagen ADC products post-acquisition

Adjusted operating margin and cost restructuring savings realization

Pipeline progression: Phase 3 trial readouts and regulatory submission timelines

Free cash flow generation and debt paydown pace toward target leverage ratios

DXY (US Dollar Index) for international revenue translation impact

M&A pharma patent debt margin expansion